Microbicide Trials Network

CLARIFICATION MEMO #04 TO:

MTN-015
An Observational Cohort Study of Women following HIV-1 Seroconversion in Microbicide Trials, Version 1.0, 19 June 2007

DAIDS Document ID 10529

Date of Clarification Memorandum: 07 July 2009

Section 1: Summary of Clarifications and Rationale

The procedures clarified in this Clarification Memorandum (CM) have been approved by the NIAID Medical Officer and are to be implemented immediately upon issuance. IRB approval of this CM is not required by the sponsor; however, investigators may submit the CM to the IRB overseeing the study at their site for information. This CM is official MTN-015 documentation and is effective immediately. A copy of this CM must be retained in each study site’s Essential Documents file for MTN-015. No change in informed consent is necessitated by or included in this CM.

The primary goal for this CM is to update the Protocol Team Roster.

Section 2: Implementation

Text to be deleted is noted by strikethrough and text to be added is noted below in bold.

1. The following updates are made to the Protocol Team Roster:

Kathy Mngadi, MBChB, MPhil, Dip HIV Man SA, Dip Epi
Site Investigator
The Aurum Institute Klerksdorp, Jade Square Building
Cnr Oliver Tambo and Margeretha Prinsloo Streets
Klerksdorp, 2571 South Africa
T: 27-18-406-4214
F: 27-18-406-4240
kmngadi@auruminstitute.org

Thesla Palanee, MMed Sci, PhD
Site Investigator
Reproductive Health and HIV Research Unit
Tshelelotso Wellness Centre
Chris Hani Baragwanath Hospital
Soweto, Johannesburg 2013 South Africa
T: 27-11-989-9269
F: 27-11-989-9294
tpalanee@rhru.co.za

The above information will be incorporated into the next version of the protocol at a later time if it is amended.